Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cytosorbents (CTSO) Revenue (2016 - 2025)

Historic Revenue for Cytosorbents (CTSO) over the last 15 years, with Q3 2025 value amounting to $9.5 million.

  • Cytosorbents' Revenue rose 1012.42% to $9.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $37.0 million, marking a year-over-year increase of 531.72%. This contributed to the annual value of $35.6 million for FY2024, which is 1450.72% up from last year.
  • Latest data reveals that Cytosorbents reported Revenue of $9.5 million as of Q3 2025, which was up 1012.42% from $9.6 million recorded in Q2 2025.
  • In the past 5 years, Cytosorbents' Revenue ranged from a high of $12.0 million in Q2 2021 and a low of $8.1 million during Q3 2022
  • Moreover, its 5-year median value for Revenue was $9.2 million (2024), whereas its average is $9.3 million.
  • As far as peak fluctuations go, Cytosorbents' Revenue soared by 2275.84% in 2021, and later crashed by 2934.54% in 2022.
  • Quarter analysis of 5 years shows Cytosorbents' Revenue stood at $10.8 million in 2021, then fell by 12.91% to $9.4 million in 2022, then dropped by 7.69% to $8.7 million in 2023, then rose by 5.56% to $9.2 million in 2024, then grew by 3.66% to $9.5 million in 2025.
  • Its Revenue was $9.5 million in Q3 2025, compared to $9.6 million in Q2 2025 and $8.7 million in Q1 2025.